Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WRAPUP 9-Markets fall on Omicron fears as officials offer vaccine reassurance

Tue, 30th Nov 2021 03:07

(Adds markets, BioNTech)

* Drugmaker's CEO warns of 'material drop' in effectiveness

* Markets fall on fears of prolonged pandemic, but partly
recover

* Time needed to see if vaccines work against Omicron

* Variant first detected in Netherlands on Nov. 19

* Japan reports first case as new variant spreads

By Ludwig Burger and Emma Thomasson

FRANKFURT/BERLIN, Nov 30 (Reuters) - Financial markets fell
sharply on Tuesday after the head of drugmaker Moderna said
existing COVID-19 vaccines would be less effective against the
new Omicron variant, but they recovered strongly after more
reassuring comments from European officials.

European Medicines Agency (EMA) executive director Emer
Cooke told the European Parliament that existing vaccines will
continue to provide protection.

Andrea Ammon, chair of the European Centre for Disease
prevention and Control (ECDC), said the cases of Omicron so far
confirmed in 10 European Union countries were mild or without
symptoms, although in younger age groups.

The Pan-European STOXX 600 index, spooked by fears that
vaccine resistance https://www.reuters.com/world/how-worried-should-we-be-about-omicron-variant-2021-11-27
might trigger restrictions that would choke off a nascent
recovery, was down 0.5% at around 1644 GMT, having fallen as
much as 1.5% in early trade.

In New York at 1605 GMT, the Dow Jones Industrial Average
and the S&P 500 respectively were down about 1.3%
and 1.26%.

"There is no world, I think, where (the effectiveness) is
the same level?.?.?. we had with Delta," Moderna CEO Stephane
Bancel told the Financial Times https://www.ft.com/content/27def1b9-b9c8-47a5-8e06-72e432e0838f.

"I think it's going to be a material drop. I just don't know
how much because we need to wait for the data. But all the
scientists I've talked to?.?.?.are like 'this is not going to be
good'."

The University of Oxford said there was no evidence that
current vaccines would not prevent severe disease from Omicron https://www.reuters.com/business/healthcare-pharmaceuticals/how-fast-does-it-spread-scientists-ask-whether-omicron-can-outrun-delta-2021-11-29,
but that it was ready to rapidly update its shot, developed
with AstraZeneca, if necessary.

LAB TESTS

Moderna could not be reached for comment.

Regeneron Pharmaceuticals said its COVID-19 antibody
cocktail and other similar antiviral treatments could be less
effective against the latest variant.

News of Omicron's emergence had wiped roughly $2 trillion
off global stocks on Friday, after it was identified in southern
Africa and announced on Nov. 25.

Yet Dutch authorities said the variant had been detected in
the Netherlands as early as Nov. 19, before two flights arrived
from South Africa that were known to have carried the virus.

Cooke said lab tests for "cross neutralisation" would take
about two weeks. If there were a need to change COVID-19
vaccines, new ones could be approved within three or four
months, she added.

"Vaccination will likely still keep you out of the
hospital," said John Wherry, director of the Penn Institute for
Immunology in Philadelphia.

Moderna and fellow drugmakers BioNTech and Johnson & Johnson
are already working on vaccines that specifically target
Omicron. Moderna has also been testing a higher dose of its
existing booster.

BioNTech and Pfizer's vaccine will likely offer
strong protection against severe disease from the new variant,
BioNTech Chief Executive Ugur Sahin told Reuters.

Sahin said he expects lab tests to show some loss of
protection against mild and moderate disease due to Omicron but
the extent of that loss was hard to predict.

But border closures have already cast a shadow over economic
recovery just as parts of Europe see a fourth wave of infections
as winter sets in.

Bank of England policymaker Catherine Mann added to downbeat
comments from U.S. Fed Chairman Jerome Powell by
saying Omicron could hit consumer confidence, which would not
only weaken the British economy's recovery but could also could
push up inflation at the same time.

Many of the new travel restrictions have focused, to South
Africa's fury, on banning flights to and from southern Africa.

Japan confirmed its first case of the new variant on
Tuesday, in a traveller from Namibia. Australia found that a
person with Omicron had visited a busy shopping centre in Sydney
while probably infectious.

BORDER CONTROLS

Britain and the United States have both pushed their booster
programmes in response to the new variant. London said
international arrivals would have to self-isolate until they get
a negative result in a PCR test.

Greece said vaccination would be compulsory for the
over-60s, the group seen as most vulnerable to COVID-19.

Australia on Monday delayed the reopening of its
international borders by two weeks, less than 36 hours before
foreign students and skilled migrants were to be allowed back.

But in Germany, a current hotspot of the previous
significant variant, Delta, the seven-day average infection rate
fell slightly for the first time in three weeks after new
restrictions to slow transmission.

Sources said chancellor-in-waiting Olaf Scholz supported
making vaccination against COVID-19 compulsory and backed
barring the unvaccinated from non-essential stores.

Neighbouring Austria, which imposed its fourth full lockdown
last week after a surge in infections, also registered a drop.

But France registered its highest daily infection tally
since April.

And the Dutch health authority said Omicron was already
spreading in the Netherlands, where intensive care beds are
running out and measures including restrictions on hospitality
have yet to take effect.

The curbs on travellers from southern Africa have
highlighted the inequality of vaccine distribution, which may
have given the virus more opportunities to mutate.

WHO head Tedros Adhanom Ghebreyesus said he understood
concerns about Omicron, but added:

"I am equally concerned that several member states are
introducing blunt, blanket measures that are not evidence-based
or effective on their own, and which will only worsen
inequities."

The passenger liner Europa was docking in Cape Town on
Tuesday in what was meant to be the official start of the first
cruise ship season in South Africa's top tourist hub since the
pandemic.

After Omicron was discovered while they were at sea, many
passengers were expected to fly straight home.

(Reporting by Reuters bureaux worldwide; Writing by Himani
Sarkar and Kevin Liffey; Editing by Shri Navratnam, Andrew
Cawthorne, Nick Macfie and Angus MacSwan)

More News
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more
25 Apr 2024 07:43

LONDON BRIEFING: Miner Anglo American eyes rival BHP takeover

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 06:30

Sanofi Q1 profit slips on generic competition, forex effects

April 25 (Reuters) - Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
18 Apr 2024 14:17

UK earnings, trading statements calendar - next 7 days

Friday 19 April 
888 Holdings PLCTrading Statement
Man Group PLCTrading Statement
Monday 22 April 
Brave Bison Group PLCFull Year Results
Elixirr International PLCFull Year Results
Frenkel Topping Group PLCFull Year Results
Mobico Group PLCFull Year Results
South32 LtdQ3 Results
Ten Lifestyle Group PLCHalf Year Results
Tuesday 23 April 
Alliance Pharma PLCFull Year Results
Alphawave IP Group PLCFull Year Results
Anglo American PLCTrading Statement
ASA International Group PLCFull Year Results
Associated British Foods PLCHalf Year Results
Eleco PLCFull Year Results
GB Group PLCTrading Statement
Jupiter Fund Management PLCTrading Statement
Maintel Holdings PLCFull Year Results
Property Franchise Group PLCFull Year Results
Taylor Wimpey PLCTrading Statement
tinyBuild IncFull Year Results
Trellus Health PLCFull Year Results
Wednesday 24 April 
1Spatial PLCFull Year Results
abrdn PLCTrading Statement
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
Lloyds Banking Group PLCQ1 Results
Nichols PLCTrading Statement
PensionBee Group PLCFirst Quarter Results
PZ Cussons PLCTrading Statement
Reckitt Benckiser Group PLCTrading Statement
Sanderson Design Group PLCFull Year Results
Serica Energy PLCFull Year Results
Star Energy Group PLCFull Year Results
Tortilla Mexican Grill PLCFull Year Results
Tracsis PLCHalf Year Results
Warpaint London PLCFull Year Results
Thursday 25 April 
Aquila European Renewables PLCFull Year Results
Argo Blockchain PLCFull Year Results
AstraZeneca PLCQ1 Results
Barclays PLCQ1 Results
Checkit PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Destiny Pharma PLCFull Year Results
Hikma Pharmaceuticals PLCTrading Statement
Focusrite PLCHalf Year Results
Ibstock PLCTrading Statement
Inchcape PLCTrading Statement
J Sainsbury PLCFull Year Results
London Stock Exchange Group PLCQ1 Results
Persimmon PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
PureTech Health PLCFull Year Results
Relx PLCTrading Statement
Renewi PLCTrading Statement
Schroders PLCQ1 Results
Skillcast Group PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
Unilever PLCQ1 Results
WAG Payment Solutions PLCTrading Statement
Weir Group PLCTrading Statement
WH Smith PLCHalf Year Results
WPP PLCTrading Statement
Zinc Media Group PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
16 Apr 2024 09:48

LONDON BROKER RATINGS: RBC raises Admiral; Barclays cuts Phoenix Group

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.